ClinicalTrials.gg

Program

MT027

A development code. Also written as “MT027 cells suspension” and “Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3”.

Its studies are mostly in Brain Neoplasms · Neurologic Manifestations · Glioma · Pleural Effusion, Malignant, led by 2 companies.

Furthest: phase 2, since Jun 11, 20245 company-led studies, 5 open or runningNext primary completion: Dec 13, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Maximum Bio-tech33 open or runningphase 1since Jun 11, 2024Jun 11, 2024none ahead
T-MAXIMUM Pharmaceutical22 open or runningphase 2since Jan 27, 2026Jan 27, 2026Dec 13, 2028phase 2 · NCT07386002

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 11, 2024First study: phase 1 study in Pleural Effusion, MalignantNew to Suzhou Maximum Bio-techSuzhou Maximum Bio-tech · NCT06726564 · 18 planned · China
  2. Dec 3, 20242 phase 1 studiesSuzhou Maximum Bio-tech · NCT06742593, NCT06737146
  3. Jan 27, 2026T-MAXIMUM Pharmaceutical's first study: phase 2 study in RecurrenceNew to T-MAXIMUM PharmaceuticalT-MAXIMUM Pharmaceutical · NCT07386002 · 40 planned · United States, Taiwan
  4. Oct 14, 2026Phase 2 study in Brain Metastases From Solid TumorsT-MAXIMUM Pharmaceutical · NCT07897799 · 40 planned · United States, Taiwan

Ahead

  1. Dec 13, 2028Primary completion: phase 2 study in RecurrenceT-MAXIMUM Pharmaceutical · NCT07386002
  2. Dec 20, 2029Primary completion: phase 2 study in Brain Metastases From Solid TumorsT-MAXIMUM Pharmaceutical · NCT07897799

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07897799Brain Metastases From Solid Tumors · United States, Taiwan2Not yet recruitingT-MAXIMUM PharmaceuticalDec 20, 202940
NCT07386002Recurrence · United States, Taiwan2Not yet recruitingT-MAXIMUM PharmaceuticalDec 13, 202840
NCT06737146Glioma · China1Not yet recruitingSuzhou Maximum Bio-techJun 30, 202612
NCT06742593Neurologic Manifestations · China1Not yet recruitingSuzhou Maximum Bio-techDec 30, 202512
NCT06726564Pleural Effusion, Malignant · China1RecruitingSuzhou Maximum Bio-techMay 202618

How it is read

Names in the registry

  • “MT027 cells suspension”, 3 entries
  • “Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3”, 2 entries

Codes read as this program: MT027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.